← Back to Search

MW151 for Cognitive Impairment Due to Brain Radiation Therapy (MW151-102 Trial)

Phase 1

Recruiting

Led By Vinai Gondi, MD

Research Sponsored by ImmunoChem Therapeutics, LLC

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

MW151-102 Trial Summary

This trial will study if MW151 can help reduce cognitive dysfunction caused by brain radiation therapy.

Who is the study for?

This trial is for adults with brain metastases from solid tumors who can consent, speak English, and have had a recent confirmation of malignancy. They must not be pregnant or have severe health issues like heart failure, infections needing IV antibiotics, jaundice due to liver problems, frequent seizures despite medication, significant psychiatric disorders or substance abuse within the last 5 years.Check my eligibility

What is being tested?

The study tests if MW151 can prevent cognitive decline when given during whole-brain radiotherapy for patients with intracranial metastases. It's based on evidence that MW151 reduces brain inflammation and improves cognition in animal models.See study design

What are the potential side effects?

While specific side effects of MW151 are not listed here, potential risks may include allergic reactions to its components as noted in the exclusion criteria. Side effects related to brain inflammation reduction will be monitored.

MW151-102 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

Secondary outcome measures

Anti-inflammatory effects

Exploratory objective: brain age analysis in patiens undergoing whole-brain radiotherapy plus MW151

Progression-free survival and overall survival

+1 more

MW151-102 Trial Design

1Treatment groups

Experimental Treatment

Group I: Safety and tolerability evaluationExperimental Treatment1 Intervention

Part A: Open Label sentinel cohort 10 subjects will receive MW151 in an open label safety evaluation. Part B: Open Label 30 subjects will receive MW151.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Northwestern MedicineOTHER

10 Previous Clinical Trials

8,502 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,664 Previous Clinical Trials

40,925,966 Total Patients Enrolled

ImmunoChem Therapeutics, LLCLead Sponsor

Media Library

MW151 Clinical Trial Eligibility Overview. Trial Name: NCT05417282 — Phase 1

Cognitive Impairment Research Study Groups: Safety and tolerability evaluation

Cognitive Impairment Clinical Trial 2023: MW151 Highlights & Side Effects. Trial Name: NCT05417282 — Phase 1

MW151 2023 Treatment Timeline for Medical Study. Trial Name: NCT05417282 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are we still looking for human participants for this experiment?

"The clinical trial is recruiting participants, as noted on clinicaltrials.gov. This information is up-to-date as of the most recent update on July 8th, 2022. The trial was originally posted on July 1st, 2020."

Answered by AI